Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation

European Journal of Cancer

Volumn 49, Issue 14, 2013, Pages 3020-3028

  Tandle, Anita T ^a   Kramp, Tamalee ^a   Kil, Whoon J ^a   Halthore, Aditya ^a   Gehlhaus, Kristen ^a   Shankavaram, Uma ^a   Tofilon, Philip J ^a   Caplen, Natasha J ^a   Camphausen, Kevin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Glioblastoma multiforme; GSK461364A; PLK1; Radiation; siRNA

Indexed keywords

DOUBLE STRANDED DNA; ENZYME INHIBITOR; GSK 461364A; HISTONE H2AX; POLO LIKE KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL KILLING; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; RADIOSENSITIZATION; RNA INTERFERENCE;

GLIOBLASTOMA MULTIFORME; GSK461364A; PLK1; RADIATION; SIRNA;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MITOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; THIOPHENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883054675     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.05.013     Document Type: Article

References (37)

1. M. Preusser, S. de Ribaupierre, and A. Wohrer Current concepts and management of glioblastoma Ann Neurol 70 1 2011 9 21
2. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 10 2005 987 996
3. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 5 2009 459 466
4. P.A. Futreal, A. Kasprzyk, E. Birney, J.C. Mullikin, R. Wooster, and M.R. Stratton Cancer and genomics Nature 409 6822 2001 850 852
5. E.C. Quant, and P.Y. Wen Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials Neuroimaging Clin N Am 20 3 2010 425 448
6. K. Holand, F. Salm, and A. Arcaro The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors Curr Cancer Drug Targets 11 2011 894 918
7. J.P. MacKeigan, L.O. Murphy, and J. Blenis Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance Nat Cell Biol 7 6 2005 591 600
8. D.A. Grueneberg, W. Li, and J.E. Davies Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines Proc Natl Acad Sci U S A 105 43 2008 16490 16495
9. B.D. Manning Challenges and opportunities in defining the essential cancer kinome Sci Signal 2 63 2009 pe15
10. L.M. Murrow, S.V. Garimella, T.L. Jones, N.J. Caplen, and S. Lipkowitz Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome Breast Cancer Res Treat 122 2 2010 347 357
11. A.M. McCord, M. Jamal, E.S. Williams, K. Camphausen, and P.J. Tofilon CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines Clin Cancer Res 15 16 2009 5145 5153
12. I.M. Buchanan, T. Scott, and A.T. Tandle Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102 J Cell Mol Med 15 9 2011 1999 2006
13. K. Strebhardt Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy Nat Rev Drug Discov 9 8 2010 643 660
14. F.D. Sigoillot, and R.W. King Vigilance and validation: keys to success in RNAi screening ACS Chem Biol 6 1 2011 47 60
15. M. Sioud Promises and challenges in developing RNAi as a research tool and therapy Methods Mol Biol 703 2011 173 187
16. S.E. Martin, Z.H. Wu, and K. Gehlhaus RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors Curr Cancer Drug Targets 11 8 2011 976 986
17. M. Bahassi el Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions Exp Biol Med (Maywood) 236 6 2011 648 657
18. Y. Degenhardt, and T. Lampkin Targeting Polo-like kinase in cancer therapy Clin Cancer Res 16 2 2010 384 389
19. C.S. Foong, E. Sandanaraj, and H.B. Brooks Glioma-propagating cells as an in vitro screening platform: PLK1 as a case study J Biomol Screen 17 9 2012 1136 1150
20. C. Lee, A. Fotovati, and J. Triscott Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice Stem Cells 30 6 2012 1064 1075
21. N. Takai, R. Hamanaka, J. Yoshimatsu, and I. Miyakawa Polo-like kinases (Plks) and cancer Oncogene 24 2 2005 287 291
22. N. Grinshtein, A. Datti, and M. Fujitani Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells Cancer Res 71 4 2011 1385 1395
23. F. Eckerdt, J. Yuan, and K. Strebhardt Polo-like kinases and oncogenesis Oncogene 24 2 2005 267 276
24. S. Yamada, M. Ohira, and H. Horie Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas Oncogene 23 35 2004 5901 5911
25. M. Steegmaier, M. Hoffmann, and A. Baum BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo Curr Biol 17 4 2007 316 322
26. S. Ackermann, F. Goeser, and J.H. Schulte Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma Clin Cancer Res 17 4 2011 731 741
27. K. Gerster, W. Shi, and B. Ng Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 77 1 2010 253 260
28. F. Rodel, S. Keppner, and G. Capalbo Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer Am J Pathol 177 2 2010 918 929
29. A.G. Morales, M.S. Brassesco, and J.A. Pezuk BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity Anticancer Drugs 22 10 2011 995 1001
30. Y. Qian, E. Hua, and K. Bisht Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain Clin Exp Metastasis 28 8 2011 899 908
31. X.S. Liu, B. Song, and B.D. Elzey Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation J Biol Chem 286 41 2011 35795 35800
32. C. Ang, M.C. Guiot, A.V. Ramanakumar, D. Roberge, and P. Kavan Clinical significance of molecular biomarkers in glioblastoma Can J Neurol Sci 37 5 2010 625 630
33. D. Koul PTEN signaling pathways in glioblastoma Cancer Biol Ther 7 9 2008 1321 1325
34. J.J. Lee, B.C. Kim, and M.J. Park PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation Cell Death Differ 18 4 2011 666 677
35. T.C. Nappi, P. Salerno, and H. Zitzelsberger Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma Cancer Res 69 5 2009 1916 1923
36. V.A. Smits, R. Klompmaker, and L. Arnaud Polo-like kinase-1 is a target of the DNA damage checkpoint Nat Cell Biol 2 9 2000 672 676
37. D. Olmos, D. Barker, and R. Sharma Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies Clin Cancer Res 17 10 2011 3420 3430